Exicure, Inc. (XCUR)
US — Healthcare Sector
Automate Your Wheel Strategy on XCUR
With Tiblio's Option Bot, you can configure your own wheel strategy including XCUR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol XCUR
- Rev/Share 0.0
- Book/Share 1.4029
- PB 4.1415
- Debt/Equity 0.0537
- CurrentRatio 1.8923
- ROIC -0.6645
- MktCap 37032179.0
- FreeCF/Share -0.819
- PFCF -7.1574
- PE -4.6564
- Debt/Assets 0.0254
- DivYield 0
- ROE -1.104
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial
XCUR
Published: December 09, 2025 by: Benzinga
Sentiment: Positive
Published: December 09, 2025 by: Benzinga
Sentiment: Positive
Exicure, Inc. (NASDAQ: XCUR) stock is trading higher on Tuesday. Its session volume was 13.62 million, compared with the average volume of 151.41 thousand, according to data from Benzinga Pro.
Read More
This BlackRock stock just rocketed 70%
XCUR
Published: December 09, 2025 by: Finbold
Sentiment: Positive
Published: December 09, 2025 by: Finbold
Sentiment: Positive
Exicure (NASDAQ: XCUR), a clinical-stage biotechnology company specializing in next-generation stem-cell mobilization therapies, has staged a massive rally as investors reacted to the company's new breakthrough products.
Read More
About Exicure, Inc. (XCUR)
- IPO Date 2018-05-22
- Website https://www.exicuretx.com
- Industry Biotechnology
- CEO Andy Yoo
- Employees 7
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.